Nasal spray lowers Covid viral load by 94 percent in 24 hours: Lancet study


PTI, Jul 16, 2022, 10:13 AM IST

Credit: iStock Photo

A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 percent within 24 hours and 99 percent in 48 hours, according to the results of a phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.

The study on Nitric Oxide Nasal Spray (NONS) was conducted by Mumbai-based pharmaceutical company Glenmark on 306 vaccinated and unvaccinated adults with symptomatic mild COVID-19 across 20 clinical sites in India.

The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. NONS was self-administered six times daily as two sprays per nostril for seven days.

The study was conducted during the Delta and Omicron surges. The research found that high-risk patients who received NONS had a significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.

Viral load was reduced by 93.7 percent within 24 hours and by 99 percent within 48 hours of treatment with NONS. Similar results were observed in vaccinated and unvaccinated populations, the authors said.

”The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS,” Monika Tandon, Senior VP & Head – Clinical Development, Glenmark, and one of the authors of the study said.

”This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in the current highly transmissible phase of pandemic,” Tandon said in a statement.

NONS was launched in India under the brand name FabiSpray in February after it received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process.

Nitric Oxide blocks entry into the nasal passage kills the virus, and stops its replication, which is why the viral load is reduced so rapidly with NONS, the statement said.

The median time to viral cure was three days in the NONS group and seven days in the placebo group after the start of the treatment, it said.

The proportion of immediate contacts having a positive COVID-19 test or becoming symptomatic, remained nearly the same in the NONS group while it numerically increased in the placebo group over the treatment, the authors added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

J&K youth ends life by jumping in Chenab, body found in Pakistan; kin seek PM Modi’s help to get back body

Centre asks Jharkhand to auction 10 mineral blocks, warns it will go ahead if state fails to do so

Congress accuses Modi govt of showing ‘insensitivity, hostility’ towards Maharashtra

Puri Jagannath temple’s Ratna Bhandar to be reopened at 1:28 pm

Gaurav Gogoi to be Congress’ deputy leader in Lok Sabha

Bejai: House ransacked, Door smashed; Chaddi Gang’s involvement suspected

Keen to be sustainable after dying? Earth to earth, cradle to compost

Related Articles More

Raise a Toast: It’s World Rum Day!

Concerns arise about Zika virus spread in Karnataka

India’s population to peak in early 2060s to 1.7 billion before declining: UN

Case study highlights hidden health risks of prolonged exposure to pigeons

Endometrial Cancer in India: An Emerging Health Challenge

MUST WATCH

Donald Trump

Elephant attack

Anant Ambani Wedding

BJP & Congress members clash

Aparna Vastarey


Latest Additions

J&K youth ends life by jumping in Chenab, body found in Pakistan; kin seek PM Modi’s help to get back body

Gaurav Gogoi to be Congress’ deputy leader in Lok Sabha

Centre asks Jharkhand to auction 10 mineral blocks, warns it will go ahead if state fails to do so

BCCI to releases Rs one crore for treatment of cancer-stricken Anshuman Gaekwad

Congress accuses Modi govt of showing ‘insensitivity, hostility’ towards Maharashtra

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.